Navigation Links
Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
Date:6/5/2011

EAST HANOVER, N.J., June 5, 2011 /PRNewswire/ -- Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking Gleevec® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment. These data will be presented at the 47th American Society of Clinical Oncology (ASCO) plenary session on Sunday, June 5.

The results show that at five years 66% of patients taking Gleevec for three years remained free of cancer recurrence (primary endpoint) compared to 48% who had received Gleevec for only one year (p<0.0001). Moreover, 92% of patients taking Gleevec for three years were alive (secondary endpoint) compared to 82% who had received Gleevec for only one year (p=0.019) (1). Median patient follow-up was 54 months.

The 400-patient Phase III trial, conducted by the Scandinavian Sarcoma Group (SSG) and the Sarcoma Group of the Arbeitsgemeinschaft Internistische Onkologie (AIO), is the first prospective multicenter clinical trial to demonstrate a survival benefit of adjuvant Gleevec therapy for KIT+ GIST with extended three years of therapy relative to one year of therapy. The side effect profile in the clinical trial was consistent with that reported in previous studies with Gleevec.

"This study confirms the hypothesis that extending the duration of Gleevec treatment for patients following surgery improves recurrence-free survival. For the first time, an effect on overall survival was found," said Heikki Joensuu, M.D., Ph.D., Professor, Oncology, University of Helsinki and principal investigator of the study. "Results from this trial may positively impact clinical practice by helping physicians create the optimal treatment plan for patients with operable KIT+ GIST."

Gastrointestinal stromal tumors are a rare, life-threatening cancer of the gastrointestinal
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
2. Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
3. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
4. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
5. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
6. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
7. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
8. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
9. Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
10. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
11. Final Approval of Novartis Gender Discrimination Settlement Slated for November 19
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... a corporate overview and update at the NewsMakers in ... at 11:30 a.m. Eastern Time (8:30 a.m. Pacific Time), ... York City . A live audio ... investor relations section of Arena,s website at www.arenapharm.com ...
(Date:9/22/2014)... and NEW YORK , Sept. ... ACCP), has signed an exclusive, global license agreement ... and commercialization of its proprietary plasma fractionation process. ... team and its intention to strategically refocus and ... its plans to pursue a national listing for ...
(Date:9/22/2014)... According to the new ... (Equipment, Media and Reagents), by Source, by type, ... Toxicity Testing, Research, Drug Discovery) - Analysis & ... and studies the major market drivers, threats, opportunities, ... data tables and 64 figures spread through 225 ...
Breaking Medicine Technology:Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4
... 16, 2011 Reportlinker.com announces that a new ... Global Cell/Tissue Culture Supplies ... This report analyzes the worldwide markets ... the following Product Segments: Media, Sera, and Reagents. ...
... YORK, March 16, 2011 Reportlinker.com announces that ... its catalogue: Global Freeze Drying ... This report analyzes the worldwide markets ... the following Product Segments: Laboratory Freeze Drying Equipment, ...
Cached Medicine Technology:Global Cell/Tissue Culture Supplies Industry 2Global Cell/Tissue Culture Supplies Industry 3Global Cell/Tissue Culture Supplies Industry 4Global Cell/Tissue Culture Supplies Industry 5Global Cell/Tissue Culture Supplies Industry 6Global Cell/Tissue Culture Supplies Industry 7Global Cell/Tissue Culture Supplies Industry 8Global Cell/Tissue Culture Supplies Industry 9Global Cell/Tissue Culture Supplies Industry 10Global Cell/Tissue Culture Supplies Industry 11Global Cell/Tissue Culture Supplies Industry 12Global Cell/Tissue Culture Supplies Industry 13Global Cell/Tissue Culture Supplies Industry 14Global Cell/Tissue Culture Supplies Industry 15Global Cell/Tissue Culture Supplies Industry 16Global Cell/Tissue Culture Supplies Industry 17Global Cell/Tissue Culture Supplies Industry 18Global Cell/Tissue Culture Supplies Industry 19Global Freeze Drying Equipment Industry 2Global Freeze Drying Equipment Industry 3Global Freeze Drying Equipment Industry 4Global Freeze Drying Equipment Industry 5Global Freeze Drying Equipment Industry 6Global Freeze Drying Equipment Industry 7Global Freeze Drying Equipment Industry 8Global Freeze Drying Equipment Industry 9Global Freeze Drying Equipment Industry 10Global Freeze Drying Equipment Industry 11Global Freeze Drying Equipment Industry 12Global Freeze Drying Equipment Industry 13Global Freeze Drying Equipment Industry 14Global Freeze Drying Equipment Industry 15
(Date:9/22/2014)... Austin, Texas (PRWEB) September 22, 2014 ... testing and treatment, will work with companies to help ... prevent the development of diabetes as part of a ... Stop Diabetes @ Work initiative. , PreDiabetes Centers ... Texas Department of Transportation in Austin on Tuesday, October ...
(Date:9/22/2014)... Steven Reinberg HealthDay Reporter ... that bacterial pneumonia can raise your risk of heart problems, ... and kill heart cells, increasing the chances of heart failure, ... report. In mice, monkeys and human heart tissue, researchers ... and they tried a vaccine that might one day prevent ...
(Date:9/22/2014)... At the 10th Clinton Global ... Partnership (SNP) announced the successful launch of a ... Risk Reduction Program for Women. The announcement of ... their risk of heart disease through a seafood-rich ... for addressing significant global challenges made by CGI ...
(Date:9/22/2014)... Burbank, CA (PRWEB) September 22, 2014 ... social and mobile recruiting, announced today an ... talent management solutions for the healthcare industry. ... to TweetMyJobs’ suite of social recruiting solutions ... management software designed specifically for healthcare organizations. ...
(Date:9/22/2014)... -- In a collaboration that will encompass a ... and patient care and accelerate personalized genomic medicine, ... Medical Center (BIDMC) have established a new academic, ... today. , A recently signed agreement calls for ... a comprehensive relationship in the areas of research ...
Breaking Medicine News(10 mins):Health News:PreDiabetes Centers to Offer Diabetes Screening at Several Companies Around Austin 2Health News:PreDiabetes Centers to Offer Diabetes Screening at Several Companies Around Austin 3Health News:Scientists Spot How Bacterial Pneumonia Damages the Heart 2Health News:Scientists Spot How Bacterial Pneumonia Damages the Heart 3Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 2Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 3Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 4Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 2Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 3Health News:TweetMyJobs and HealthcareSource Partner To Provide Social Recruiting Solutions to Healthcare Organizations 4Health News:The Jackson Laboratory and BIDMC announce multifaceted affiliation 2Health News:The Jackson Laboratory and BIDMC announce multifaceted affiliation 3
... , TUESDAY, Aug. 9 (HealthDay News) -- Motion ... changing the way cars take curves, researchers say. They ... tilt only at the beginning and end of curves rather ... motion sickness. "This is a major breakthrough and a ...
... BOSTON Beth Israel Deaconess Medical Center (BIDMC) researchers ... been awarded Challenge Awards of $1 million each from ... teams of investigators in their pursuit of new treatments ... Awards will support a total of 10 scientific projects ...
... Concern about the capacity of individuals with schizophrenia to ... impairment due to psychotic symptoms associated with the disorder. ... that prospective participants make when undergoing a formal assessment ... in IRB: Ethics & Human Research ...
... 221.10.254.64 COLUMBIA, Mo. Due to changing guidelines ... screened for breast cancer with mammograms, many women are ... and older get a mammogram every year, but the ... year for women older than 50. A University of ...
... By Kathleen Doheny HealthDay Reporter , MONDAY, ... as a healthier alternative to estrogen for maintaining bone ... according to a new study. , "Our study shows ... not prevent bone loss or alleviate menopausal symptoms," said ...
... As parents prepare to send their children back to school, ... in academic performance, an expert advises. Studies have shown ... more alert throughout the school day and also earn higher ... Pat Alfaro, clinical manager of the division of nutrition therapy ...
Cached Medicine News:Health News:Going Full-Tilt Into Turns May Ease Motion Sickness on Trains 2Health News:BIDMC scientists receive Challenge Awards from Prostate Cancer Foundation 2Health News:Schizophrenia study finds cognitive deficits significantly impair decision-making capacity 2Health News:Doctors, women should spend more time discussing mammograms 2Health News:Soy Supplements Don't Ease Bone Loss, Menopausal Symptoms: Study 2Health News:Soy Supplements Don't Ease Bone Loss, Menopausal Symptoms: Study 3Health News:Healthy Lunch and Breakfast Keep Students Alert 2
... Aprons are the result of a technologically ... x-ray aprons. Constructed with a wear resistant, ... the Lead Free aprons exhibit the same ... Each apron weighs approximately 50% less than ...
... Pre-sterilized Medtronic Electrodes are made ... Polytetrafluoretylene. The exposed tip of ... and serves as the recording ... are available. Each needle is ...
... Cadwell Easy II is an advanced multi-modality ... a complete package that includes our 32-channel ... pair connectors for recording channels like airflow, ... a DC amplifier with four DC inputs, ...
... II EEG system is a fully digital 32-channel ... any practice or hospital need. It can be ... a laptop computer for out-of-lab data collection, or ... custom designed carts that will hold a high ...
Medicine Products: